FibroGen (NASDAQ:FGEN) Earns “Market Perform” Rating from William Blair

William Blair reaffirmed their market perform rating on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Wednesday,RTT News reports.

Separately, StockNews.com initiated coverage on FibroGen in a research report on Wednesday, November 6th. They issued a “hold” rating on the stock.

FibroGen Price Performance

NASDAQ FGEN opened at $0.33 on Wednesday. The company has a 50-day moving average of $0.36 and a 200-day moving average of $0.71. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.93. The company has a market cap of $33.73 million, a P/E ratio of -0.27 and a beta of 0.72.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same period last year, the company posted ($0.52) EPS. As a group, equities research analysts anticipate that FibroGen will post -1.12 EPS for the current year.

Institutional Trading of FibroGen

Institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in FibroGen during the first quarter worth approximately $131,000. Acadian Asset Management LLC boosted its position in FibroGen by 1.4% during the 1st quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after purchasing an additional 34,937 shares during the period. Delap Wealth Advisory LLC acquired a new stake in FibroGen in the 1st quarter valued at $27,000. Alpine Global Management LLC purchased a new position in FibroGen in the first quarter valued at about $25,000. Finally, Accel Wealth Management lifted its stake in shares of FibroGen by 117.5% during the second quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 51,645 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.